Related Experiment Videos
[Phase I clinical study of 99mTc-MAG3]
K Ishii1, A Ishibashi, K Torizuka
1Department of Radiology, Kitasato University School of Medicine, Kanagawa.
Kaku Igaku. the Japanese Journal of Nuclear Medicine
|February 1, 1993
Summary
This study found 99mTc-MAG3 to be a safe and effective agent for renal imaging. It demonstrated good biodistribution and high safety, making it promising for diagnosing renal dynamic function.
Area of Science:
- Nuclear Medicine
- Radiopharmaceutical Development
Background:
- 99mTc-MAG3 was developed as a novel agent for renal scintigraphy and renography.
- Evaluating new radiopharmaceuticals is crucial for advancing diagnostic capabilities.
Purpose of the Study:
- To assess the safety and biodistribution of 99mTc-MAG3 in normal volunteers.
- To determine the efficacy of 99mTc-MAG3 in renal dynamic function imaging.
Main Methods:
- Phase I clinical study involving three healthy volunteers.
- Administration of 99mTc-MAG3 followed by safety monitoring (vital signs, lab data).
- Renal scintigraphy and renography performed post-injection; biodistribution and urinary excretion quantified.
Main Results:
- No significant adverse reactions or safety concerns were observed.
- Rapid blood clearance and urinary excretion of 99mTc-MAG3 were confirmed.
- High-quality renal images and renograms were obtained, with peak renogram time around 3 minutes.
- Cumulative urinary excretion reached 77.1% at 30 min and 94.1% at 3 hours.
- Estimated radiation dose to the bladder (5.78 mGy/200 MBq) is within permissible limits.
Conclusions:
- 99mTc-MAG3 exhibits a high safety profile.
- The agent demonstrates excellent biodistribution and rapid renal clearance.
- 99mTc-MAG3 is a promising radiopharmaceutical for diagnosing renal dynamic function.